Meeting Report
IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Alexis C. Geppner, MLS, CTTS, PA-C
J Adv Pract Oncol 2022;13(suppl 1):12–14 |
https://doi.org/10.6004/jadpro.2022.13.1.11 |
© 2022 Harborside™
ABSTRACT
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, distills information reviewed in the session on IDH-mutated acute myeloid leukemia presented by Courtney D. DiNardo, MD, MSCE, also of MD Anderson Cancer Center, at the 2021 SOHO Annual Meeting.
For access to the full length article, please
sign in.
